19327-38-9 Purity
96%
If you have any other questions or need other size, please get a quote.
Specification
Reference: [1]Location in patent: experimental part
Chai, Yun; Wan, Zhi-Long; Wang, Bo; Guo, Hui-Yuan; Liu, Ming-Liang
[European Journal of Medicinal Chemistry, 2009, vol. 44, # 10, p. 4063 - 4069]
[2]Current Patent Assignee: KIRIN HOLDINGS CO LTD; TAKEDA PHARMACEUTICAL COMPANY LIMITED - US2005/70549, 2005, A1
[3]Current Patent Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED; Kyowa Kirin (in: Kirin Holdings); KIRIN HOLDINGS CO LTD - US2016/31908, 2016, A1
Location in patent: Paragraph 1393
[4]Current Patent Assignee: SPERO THERAPEUTICS INC - US2012/88750, 2012, A1
Location in patent: Page/Page column 28; 29
[5]Current Patent Assignee: JOHNSON & JOHNSON INC; IDORSIA PHARMACEUTICALS LTD - WO2018/19929, 2018, A1
Location in patent: Page/Page column 214
Reference: [1]Current Patent Assignee: KIRIN HOLDINGS CO LTD; TAKEDA PHARMACEUTICAL COMPANY LIMITED - US2005/70549, 2005, A1
[2]Current Patent Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED; Kyowa Kirin (in: Kirin Holdings); KIRIN HOLDINGS CO LTD - US2016/31908, 2016, A1
Location in patent: Paragraph 1394
* For details of the synthesis route, please refer to the original source to ensure accuracy.